

# ENHANCED SURGICAL OUTCOMES START AT THE SURFACE

Assessing gland function and  
structure and treating Meibomian  
Gland Dysfunction (MGD) with  
the Johnson & Johnson Vision  
TearScience product suite



# Optimizing, maintaining and restoring ocular surface health

The Johnson & Johnson Vision TearScience product suite is a proven set of tools that allow you to accurately assess gland function and structure and effectively treat MGD.

Restoring gland function improves the lipid layer of the tear film,<sup>1</sup> enabling a healthier ocular surface and an improvement in ocular surface disease symptoms,<sup>2,3</sup> including vision quality,<sup>4</sup> post-surgical outcomes and patient satisfaction.<sup>5</sup>

## THE MEIBOMIAM GLAND PRODUCT SUITE ENABLES SUCCESS

- 1** **Elevates** your status as a leader in ocular surface health, transforming patient care
- 2** **Optimizes** ocular surface health and outcomes for your patients<sup>6,7</sup>
- 3** **Automates** the treatment of MGD, a root cause of ocular surface disease symptoms, including dryness, fluctuating vision and optical aberrations<sup>3,4</sup>







## Achieve greater surgical success

On average, 60% of patients in a practice for cataract pre-surgical workups have signs of MGD<sup>8</sup> – a primary cause of sub-optimal post-surgical vision instability and post-surgical ocular surface disease. **Approximately 1 in 2 are asymptomatic.**<sup>9,10</sup>

Proactively treating MGD with **LipiFlow®** prior to surgery improves meibomian gland function, optimizing the tear film for:

- **Decreased** ocular surface symptoms in the post-surgical period<sup>4</sup>
- **Optimized** vision-related function scores in the post-surgical period<sup>4</sup>

In one study, the treatment of MGD with **LipiFlow®** improved keratometry readings and IOL selection for surgical patients.<sup>4,11</sup>




# MGD IS A CHRONIC, PROGRESSIVE AND OBSTRUCTIVE CONDITION<sup>12,13</sup>

MGD is characterized by gland obstruction, low secretions, and gland atrophy.<sup>14</sup>

OVER  
**1 IN 5**  
PATIENTS




DON'T PRESENT  
WITH SYMPTOMS<sup>15</sup>



Functioning oil  
gland secretion


If left untreated, MGD can lead to alterations of the tear film, symptoms of eye irritation, clinically apparent inflammation and ocular surface disease.<sup>16,17</sup>



No oil  
gland secretion

# MGD IS A LEADING CAUSE OF DRY EYE DISEASE<sup>17</sup>


- MGD is **highly prevalent** in the general ophthalmic population<sup>17</sup>
- In one study, **86%** of patients with Dry Eye had Meibomian Gland Dysfunction (MGD)<sup>18</sup>
- Over **745 million** people worldwide suffer from Dry Eye<sup>19</sup>



\*Both eyes of 299 healthy patients and those with dry eye disease (218 women, 81 men) were evaluated using Schirmer tests and MGD (Foulks-Bron scoring) across 10 sites in the EU and US. Adapted from: Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of Aqueous-Deficient and Evaporative Dry Eye in a Clinic-Based Patient Cohort. Cornea. 2012; 31(5): 472-478. doi:10.1097/ico.0b013e318225415a

MGD AFFECTS MORE THAN  
50% OF CATARACT PATIENTS<sup>8</sup>

SYMPTOMS OF  
UNTREATED  
**MGD**



HAVE BEEN SHOWN  
TO WORSEN AFTER  
CATARACT SURGERY<sup>10</sup>

~**50%**



OF CATARACT PATIENTS  
WITH MGD DO NOT  
SHOW SYMPTOMS<sup>9,10</sup>



PRODUCING A **HEALTHY, STABLE TEAR-FILM** IS THE  
**PRIMARY OUTCOME** FOR THE MANAGEMENT OF MGD<sup>20</sup>



**EVALUATE.**  
**TREAT.**  
**SUCCEED.**




**EVALUATE.**

The Meibomian Gland Evaluator™ (MGE) provides standardized, repeatable evaluation of meibomian gland function.<sup>21,22</sup>

# MGE: A SIMPLE WAY TO ROUTINELY EVALUATE GLAND FUNCTION


The Meibomian Gland Evaluator (MGE) can easily be added into routine eye exams.

A handheld instrument that provides a standardized, repeatable evaluation of meibomian gland function by applying the pressure of a deliberate blink, while observing gland secretions through a slit lamp.



# EVALUATE HOW MEIBOMIAN GLAND FUNCTION IS CHANGING OVER TIME

By comparing gland secretion scores at different patient visits, the MGE helps you quickly and easily assess gland function, track progression and treatment response both before and after treatment interventions.





**EVALUATE.**  
**TREAT.**  
**SUCCEED.**



*TearScience®*  
**LIPISCAN®**  
DYNAMIC MEIBOMIAN IMAGER

**EVALUATE.**

With a small footprint and user-friendly design, the durable yet lightweight **LipiScan®** with **Dynamic Meibomian Imaging™** (DMI) was designed to make high-definition meibography accessible for any practice.

# INCLUDE LIPISCAN® IN EVERY EXAM

Dynamic meibomian imager provides high-definition gland images.<sup>23</sup>


- **Small footprint and lightweight** for optimal versatility
- **Fast and intuitive** operation for seamless integration into routine workups
- **Renders high-definition images** of meibomian gland structures
- **DICOM compatibility** to export image to EMR

**LipiScan®** maximizes workflow with fast capture of meibomian gland images

Quickly image an eyelid in about 10 seconds.


## IMAGE GLANDS QUICKLY, EASILY AND EFFICIENTLY IN HD WITH LIPISCAN®

Three modes of illumination  
for greater insight:




### Dynamic Illumination

Surface lighting originates from multiple light sources to minimize reflection



### Adaptive Transillumination

Changes to the light intensity across the surface of the illuminator compensate for the lid thickness variations between patients



### Dual-Mode DMI

A combination of Dynamic Illumination and Adaptive Transillumination offers an enhanced view of meibomian gland structure



**EVALUATE.**  
**TREAT.**  
**SUCCEED.**



*TearScience®*  
**LIPIVIEW® II**  
OCULAR SURFACE INTERFEROMETER

**EVALUATE.**

The LipiView® II Ocular Surface Interferometer with **Dynamic Meibomian Imaging™** measures lipid layer thickness with nanometer accuracy, captures blink dynamics and images meibomian gland structure.


# LIPID LAYER THICKNESS MEASUREMENT AND GLAND IMAGING WITH LIPIVIEW® 24-26

Dynamic Meibomian Imager features patented technology that provides a sophisticated assessment of factors that contribute to dry eye:<sup>27</sup>

- **Real-time visualization** of the lipid layer to evaluate the dynamic response of lipids to blinking
- **Patented noise canceling technology** to measure sub-micron thickness of the lipid layer
- **Video and analysis** of blink dynamics
- **High-definition imaging** with Dynamic Meibomian Imaging

## LIPIVIEW® II OFFERS REAL-TIME REPORTING AND VISUALIZATION<sup>27</sup>

Evaluate the dynamic response of the lipids to blinking, while unique algorithms measure the extent of lid closure during each blink.\*



### Lipid Layer Thickness

Presents lipid layer thickness in an easy-to-understand color-coded map

### Dynamic Meibomian Gland Imaging

Utilizes advanced illumination technology to capture high-definition images

### Blink Dynamics

Analyzes blink patterns and detects partial blinks



EVALUATE.  
**TREAT.**  
SUCCEED.



TearScience®  
**LipiFlow®**  
THERMAL PULSATION

**TREAT.**

The LipiFlow® System's drug-free mechanism of action applies precise heat and pressure to remove gland obstructions, while protecting delicate structures of the eye.<sup>3</sup>

# LIPIFLOW® REMOVES GLAND OBSTRUCTIONS BY TREATING FROM THE INNER LID<sup>2,3</sup>

Exclusive Vectored Thermal Pulsation System features a drug-free mechanism of action:\*

\*A topical anesthetic is used at the beginning of the treatment procedure to ease patient discomfort for device placement.

## SAFELY AND EFFECTIVELY TARGETS EVERY GLAND, ON EVERY LID, FOR EACH PATIENT<sup>2,3</sup>


- Nominal inner lid therapeutic temperature
- Vaulted design protects the cornea, while multi-point sensors monitor and regulate heat and pressure
- Phased proximal-to-distal peristaltic motion helps express the contents from the glands more effectively
- Proprietary heating technology ensures precise temperature regulation and consistent heat application

- Simultaneously applies gentle peristaltic **pressure and heat** to both upper and lower lids to liquefy obstruction and remove from glands<sup>2,3</sup>
- **No drugs are required** for the procedure, after an initial anesthetic drop<sup>2</sup>

## TREAT THE OBSTRUCTION TO TREAT MGD<sup>28,29</sup>

**LipiFlow®** delivers a patented combination of targeted heat and therapeutic massage to both the upper and lower lids to remove obstruction and improve gland function, shown to **increase gland secretion scores by three-fold** on average.<sup>2,28</sup>

Advanced Vectored Thermal Pulse Technology maximizes gland clearing, while protecting the delicate structures of the eye from both heat and pressure.<sup>3</sup>






# LIPIFLOW® IS THE ONLY AUTOMATED TREATMENT TO APPLY SIMULTANEOUS PRESSURE AND HEAT TO THE INNER EYELID<sup>24,30-32</sup>

- An efficient, single-dose, 12-minute in-office procedure<sup>2</sup>
- Improves patient experience by avoiding manual expression and addressing the limitations of conventional MGD treatment<sup>2</sup>

## INFLATION TECHNOLOGY

Pressure sensors in the console ensure the application of safe levels of pressure.<sup>2</sup>



## VAULTED CORNEA SHIELD

Insulation protects the cornea from exceeding a safe temperature, while an intelligent pressure feedback loop sends pulsed sequences to expel blockages and stagnant material from the gland. The vaulted design protects the delicate structures of the eye from both heat and pressure.<sup>2</sup>

## LID WARMER

Redundant sensors within the lid warmer protect against unsafe temperatures.<sup>2</sup>

# THE SAFETY AND EFFICACY OF LIPIFLOW® HAVE BEEN WELL STUDIED<sup>28</sup>

**400K+**  
treatments  
worldwide and  
growing<sup>34</sup>

**15**  
prospective randomized  
and controlled  
trials<sup>3,4,6,20,31,32,35-43</sup>



**50+**  
peer-reviewed  
reports<sup>3,4,6,20,31,32,35-43</sup>

**10+**  
years of  
research

**Disclaimer:** Information based on internal competitive data as of June 2018 against TearScience and iLux Systems in the US.





## Treating MGD with **LipiFlow**<sup>®</sup> improves the ocular surface by stabilizing the tear film,<sup>5</sup> an important step prior to surgery<sup>44,45</sup>

Failure to manage OSD due to MGD before cataract surgery could potentially result in:<sup>45</sup>

- Unsatisfactory vision
- Refractive misses
- Fluctuating vision
- Induced higher-order aberrations
- New and/or worsened symptoms
- Redness
- Pain
- Post-operative infection such as endophthalmitis

**LipiFlow**<sup>®</sup> optimizes tear film homeostasis by improving the lipid layer, tear film stability and reducing inflammation<sup>28,46,47</sup>





Whether post-surgical results  
or a lifetime of eye health, the  
Johnson & Johnson Vision  
portfolio of products enables  
improved or excellent outcomes  
for your patients.

EVALUATE.  
TREAT.  
SUCCEED.

## References:

- Willcox MDP, et al. DEWS II Tear Film Report. *Ocul Surf* 2017;15:366-403. REF2018TS4196.
- LipiFlow®** iFLU – Doc. #011390-INT. Rev D – Sep. 2020. REF2021TS4012.
- Lane SS, et al. A New System, the LipiFlow, for the Treatment of Meibomian Gland Dysfunction (MGD). *Cornea* 2012;31(4):396-404. REF20170TH0234.
- Murakami D. Claims Substantiation Memo – Dec. 12, 2019. REF2019TS4124.
- Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery – Final Study NCT01808560. ClinicalTrials.gov. Sep. 3, 2018. REF2019TS4092.
- Blackie CA, et al. The sustained effect (12 months) of a single-dose vectored thermal pulsation procedure for meibomian gland dysfunction and evaporative dry eye. *Clin Ophthalmol* 2016;10:1385-96. REF2018TS4059.
- Pang SP, et al. Efficacy of Vectored Thermal Pulsation and Warm Compress Treatments in Meibomian Gland Dysfunction: A Meta-Analysis of Randomized Controlled Trials. *Cornea* 2019;38(6):690-697. REF2019TS4052.
- Trattler WS, et al. The prospective health assessment of cataract patient (PHACO) study: the effect of dry eye. *Clin Ophthalmol* 2017;11:1423-1430. REF2019TS4026.
- Gupta PK, et al. Prevalence of ocular surface dysfunction in patients presenting for cataract surgery. *J Cataract Refract Surg* 2018;44(9):1090-1096. REF2019TS4105.
- Cochener B, et al. Prevalence of meibomian gland dysfunction at the time of cataract surgery. *J Cataract Refract Surg* 2018;44(2):144-148. REF2018TS4020.
- Matossian C. Effect of Thermal Pulsation System Treatment on Keratometry Measurements: Prior to Cataract Surgery. ASCRS Sand Diego, Ca, May 6, 2019. REF2019TS4100.
- Nichols KK, et al. A murine model of characterizing glandular changes in obstructive meibomian gland dysfunction. ARVO 2014. Abstract #13-A0002. REF2021MLT4010.
- Schaumberg DA, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for MGD. *Invest Ophthalmol Vis Sci* 2011 Mar. 30;52(4):1994-2005. REF2018TS4007.
- 2007 Report of the International Dry Eye WorkShop (DEWS). P. 21. REF2016CN0008.
- Viso E, et al. Prevalence of asymptomatic and symptomatic meibomian gland dysfunction in the general population of Spain. *Invest Ophthalmol Vis Sci* 2012;53(6):2601-2606. REF20180TH4456.
- Craig JP, et al. TFOS DEWS II Definition and Classification Report. *Ocul Surf* 2017 Jul;15(3):276-283. REF2018TS4034.
- Nichols KK, et al. The international workshop on meibomian gland dysfunction: executive summary. *Invest Ophthalmol Vis Sci* 2011; 52(4):1922-9. REF20170TH0239.
- Lemp MA, et al. Distribution of Aqueous-Deficient and Evaporative Dry Eye in a Clinic-Based Patient Cohort. *Cornea* 2012;31(5):472-478. REF20190TH4479.
- Market Scope 2019 – Dry Eye Report. P. 10. REF2020TS4003.
- Finis D, et al. Six-month effects of a thermodynamic treatment for MGD and implications of meibomian gland atrophy. *Cornea* 2014;33(12):1265-1270. REF20170TH0237.
- Meibomian Gland Evaluator, Model MGE-1000, iFLU. Doc. #010112. Rev. N, June 3, 2018. P. 1. REF2018TS4164.
- Korb DR, Blackie CA. Meibomian gland diagnostic expressibility: correlation with dry eye symptoms and gland location. *Cornea* 2008 Dec;27(10):1142-7. Abstract. REF2018TS4079.
- LipiScan®** iFLU – Doc. #013075-ENG. Rev. E. Sep. 2020. REF2021TS4011.
- Borrmann L. Dry Eye Disease Landscape Assessment – Technology and Product Targets. June 29, 2018. REF2020MLT4008.
- Quantel Medical – LACRYDIAG – Ocular Surface Analyser. Accessed January 13, 2020. REF2020MLT4005.
- The OCULUS Keratograph® 5M – Software. Accessed Nov. 4, 2018. REF2018TS4114.
- LipiView II®** iFLU – 012051-INT. Rev. F. Sep. 2020. REF2021TS4026.
- Blackie CA, et al. Treatment for meibomian gland dysfunction and dry eye symptoms with a single-dose vectored thermal pulsation: a review. *Curr Opin Ophthalmol* 2015;26(4):306-313. REF2018TS4010.
- Friedland BR, Fleming CP. A novel thermodynamic treatment for meibomian gland dysfunction. *Curr Eye Res* 2011 Feb; 36(2):79-87. REF20180TH0083.
- Internal competitive and patent analysis. See iLux website <http://www.tearfilm.com/ilux-device/> and TearCare website <https://sightssciences.com/us/products/tear-care/>. REF2020MLT4004.
- Tauber J, et al. Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial. *Clin Ophthalmol* 2020;14:405-418. REF2022TS4007.
- Gupta PK, et al. TearCare for the Treatment of Meibomian Gland Dysfunction in Adult Patients With Dry Eye Disease: A Masked Randomized Controlled Trial. *Cornea* 2021;00:1-10. REF2022TS4008.
- Blackie CA, et al. A single-vectored thermal pulsation treatment for meibomian gland dysfunction, increases mean comfortable contact lens wearing time by approximately 4 hours per day. *Clin Ophthalmol* 2018 Jan;12:169-183. REF2018TS4018.
- Data on file – REF2020TS4017.
- Hagen KB, et al. Comparison of a single-dose vectored thermal pulsation procedure with a 3-month course of daily oral doxycycline for moderate-to-severe meibomian gland dysfunction. *Clin Ophthalmol* 2018;12:161-168. REF20180TH0043.
- Finis D, et al. Evaluation of an automated thermodynamic treatment (LipiFlow®) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial. *Ocul Surf* 2014;12(2):146-154. REF20180TH4012.
- Baumann A, Cochener B. Meibomian gland dysfunction: a comparative study of modern treatments. *J Fr Ophthalmol* 2014;37(4):303-312. Abstract. REF2019TS4111.
- Zhao Y, et al. Preoperative Management of MGD with Vectored Thermal Pulsation before Cataract Surgery: A Prospective, Controlled Clinical Trial. *Semin Ophthalmol*. 2021 Feb 15:1-7. REF2022TS4009.
- Kasetsuwan N, et al. The Efficacy Between Conventional Lid Hygiene and Additional Thermal Pulsatile System in Meibomian Gland Dysfunction Patients Treated with Long-Term Anti-Glaucoma Medications in a Randomized Controlled Trial. *Clinical Ophthalmology*. 2020;14:2891-2902. REF2022TS4010.
- Ho JZ, Zhong M. Comparative study between the Meibomian pulsation system and the warm compress treatment for MGD. *Guoji Yanke Zazhi (Int Eye Sci)*. 2018;18(7):1324-28 (Chinese). REF2022TS4011.
- Li S, et al. Effect of a Novel Thermostatic Device on Meibomian Gland Dysfunction: A Randomized Controlled Trial in Chinese Patients. *Ophthalmol Ther*. 2021 Nov 25. doi: 10.1007/s40123-021-00431-5. REF2022TS4012.
- Tauber J. A 6-Week, Prospective, Randomized, Single-Masked Study of Lifitegrast Ophthalmic Solution 5% Versus Thermal Pulsation Procedure for Treatment of Inflammatory Meibomian Gland Dysfunction. *Cornea*. 2020;39(4):403-07. REF2022TS4013.
- Park J, et al. Effects of LipiFlow Treatment Prior to Cataract Surgery: A Prospective, Randomized, Controlled Study. *American Journal of Ophthalmology*. 2021. REF2022TS4014.
- ASCRS Cornea Clinical Committee. An algorithm for the preoperative diagnosis and treatment of ocular surface disorders. *J Cataract Refract Surg* 2019;45:669-84. PP2019TS4266.
- Starr CE, et al. An algorithm for the preoperative diagnosis and treatment of ocular surface disorders. *J Cataract Refract Surg* 2019;45(5):669-684. REF2019TS4104.
- Kim MJ, et al. Effect of thermal pulsation treatment on tear film parameters in dry eye disease patients. *Clin Ophthalmol* 2017;11:883-86. REF2019TS4107.
- Karunakaran A, et al. Thermal Pulsation Therapy Alters Tear Cytokines and Alleviates Evaporative Dry Eye Signs and Symptoms. *AAO Annual Meeting San Francisco, CA*, October 12, 2019. REF2019TS4125.

For healthcare professionals only. Please reference the Instructions for Use for a complete list of Indications and Important Safety Information and contact our specialists in case of any question.